Inclusion Criteria:  Histological confirmed primary SCC of the vulva T1 tumor, not encroaching urethra/vagina/anus Depth of invasion > 1mm Tumor diameter < 4cm Unifocal tumor No enlarged (>1.5cm) or suspicious inguinofemoral lymph nodes at imaging (CT/MRI/ultrasound) Possibility to obtain informed consent Metastatic sentinel lymph node; size of metastasis > 2mm and / or extracapsular extension, or Metastatic sentinel lymph node: more than 1 SN with metastasis ≤ 2mm Patients are able to understand requirements of study, provide written informed consent and comply with the study and follow-up procedures  Adequate bone marrow, renal and liver function:  Absolute neutrophil count ≥ 1.5 x 109 /L Platelet count ≥ 100 x 109 /L Creatinine clearance ≥ 40 ml/min measured by the Cockroft Gault formula Total bilirubin < 1.25 x ULN Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN Performance status of 0, 1 or 2 on the Eastern Cooperative Oncology Group (ECOG) Scale (Appendix A) Age 18 years or older Life expectancy of ≥ 12 weeks Written informed consent  Exclusion Criteria:  Inoperable tumors and tumors > 4cm Multifocal tumors Tumors with other pathology than squamous cell carcinoma Patients with enlarged / suspicious lymph nodes which are proven metastatic after fine needle aspiration cytology No other carcinomas, other than basal cell carcinomas, within last 5 years History of pelvic radiotherapy History of any infection requiring hospitalization or antibiotics within 2 weeks before enrollment Pregnant female or nursing mother Desire to become pregnant Known brain or spinal cord metastases unless adequately treated (surgery or radiotherapy) with no evidence of progression and neurologically stable off anticonvulsants and steroids Unstable angina, myocardial infarction, cerebrovascular accident, > Class II congestive heart failure according to the New York Heart Association Classification for Congestive Heart Failure (see Appendix B) within 6 months before enrollment